glp-1 and substance use disorder IUPHAR review – Glucagon-like peptide-1 (GLP-1) disorders: An emerging pharmacotherapeutic target GLP-1 Drugs and Eating Disorders:

Many patients describe a gradual diminishment of hunger cues, reduced food cravings (particularly for high-calorie or high-fat foods), and earlier satiety during meals

Good dietary sources include leafy greens, nuts, seeds, and whole grains

2 Patient results pretreatment showed an elevated fibrinogen, CD62p, PAC-1, and platelet aggregation rates when compared to the controls, while NO was lower in this cohort when compared to controls

Brain studies showed that tirzepatide blunted surges of dopamine , a neurotransmitter deeply involved in reward and reinforcement

Hydrogen atoms were first added at a simulated pH of 7.0 by means of the pdb2pqr 58 and propka 59 software, and the protonation of titratable side chains was checked by visual inspection

The volume and concentration of compounded tirzepatide also influence reaction severity